Trial Profile
Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Every Three Week Docetaxel (Taxotere®) In Subjects With Androgen Independent Prostate Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Docetaxel; Prednisone
- Indications Prostate cancer
- Focus Adverse reactions
- 21 Jun 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01378091).
- 16 Jun 2009 New trial record.
- 02 Jun 2009 Results presented at ASCO 2009.